Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Amortization - GoodwillCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares Issued
Ratios

Legend Biotech (LEGN) EBIAT (2019 - 2025)

Legend Biotech filings provide 7 years of EBIAT readings, the most recent being $30.9 million for Q4 2025.

  • On a quarterly basis, EBIAT rose 17.05% to $30.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$235.1 million, a 32.88% decrease, with the full-year FY2025 number at $296.8 million, up 67.68% from a year prior.
  • EBIAT hit $30.9 million in Q4 2025 for Legend Biotech, up from -$39.7 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $30.9 million in Q4 2025 to a low of -$199.1 million in Q2 2023.
  • Median EBIAT over the past 5 years was -$86.6 million (2021), compared with a mean of -$76.8 million.
  • Biggest five-year swings in EBIAT: crashed 35570.18% in 2022 and later surged 18329.78% in 2024.
  • Legend Biotech's EBIAT stood at -$88.3 million in 2021, then plummeted by 53.82% to -$135.9 million in 2022, then skyrocketed by 99.89% to -$144818.0 in 2023, then surged by 18329.78% to $26.4 million in 2024, then grew by 17.05% to $30.9 million in 2025.
  • The last three reported values for EBIAT were $30.9 million (Q4 2025), -$39.7 million (Q3 2025), and -$125.4 million (Q2 2025) per Business Quant data.